Multiple ALK tyrosine kinase inhibitors (TKIs) with excellent efficacy, including first-generation crizotinib, second-generation ceritinib, alectinib, and brigatinib, and third-generation lorlatinib, have been approved for treating ALK-rearranged NSCLC patients. Here, ALK is linked to non-small cell lung carcinoma.